Review the Research<\/p>\n
Get summaries of key research on vitamin D and COVID-19<\/h5><\/div><\/div><\/div><\/div><\/div>\nHigh-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study<\/span><\/span><\/span><\/h1><\/div>Take Home Message<\/span><\/h2><\/div>In this observational study, treatment with cholecalciferol booster therapy, regardless of baseline serum 25(OH)D levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with COVID-19. <\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Who<\/span><\/h2><\/div>A total of 986 <\/span>i<\/span>n-patients with a clinical diagnosis of COVID-19 recruited from three UK hospital<\/span>s<\/span>, of whom 151 (16.0%)<\/span> received cholecalciferol booster therapy.\u00a0<\/span>\u00a0<\/span><\/p>\n\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Length of Study
\n<\/span><\/p><\/h2><\/div>Patients recruited were admitted between January<\/span> 27,<\/span> 2020 and August<\/span> 5,<\/span> 2020, and data were<\/span> collected retrospectively between June<\/span> 26,<\/span> 2020 and August<\/span> 7,<\/span> 2020.<\/span>\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/b>Results<\/span><\/h2><\/div><\/div><\/div>\n- S<\/span>erum 25(OH)D levels were not associated with COVID-19 mortality in<\/span> either<\/span> the <\/span>primary <\/span>or<\/span> validation cohort, and deficient vitamin D status <\/span>(defined as <25 nmol\/L) <\/span>was not associated with COVID-19<\/span> mortality in the primary cohort.\u00a0<\/span>\u00a0<\/span><\/li>\n
- T<\/span>reatment with <\/span>high-dose <\/span>cholecalciferol <\/span>booster therapy was associated with a reduced risk of COVID-19 mortality <\/span>regardless of baseline serum 25(OH)D levels, and this <\/span>was true in both<\/span> cohorts.<\/span>\u00a0<\/span><\/li>\n<\/ul>\n<\/div><\/div><\/div>
![](\"http:\/\/vitamindandme.org\/wp-content\/uploads\/2021\/05\/6Ling_FINAL_iStock-1221032250.jpg\")
<\/span><\/div><\/div><\/div><\/div><\/div>Things to Keep in Mind<\/span><\/h2><\/div>\n- N<\/span>ot all patients had serum 25(OH)D<\/span> levels available, so <\/span>the <\/span>power <\/span>would <\/span>have been improved with more values.\u00a0<\/span>\u00a0<\/span><\/li>\n
- W<\/span>hile <\/span>the <\/span>results<\/span> are potentially generali<\/span>z<\/span>able to the UK, <\/span>similar studies<\/span> would need to be replicated in d<\/span>iff<\/span>erent <\/span>global<\/span> populations to assess <\/span>th<\/span>eir general validity.<\/span>\u00a0<\/span><\/li>\n
- D<\/span>ue to the<\/span> cross-sectional nature of this study, <\/span>the investigators <\/span>were<\/span> unable to ascertain cause and <\/span>eff<\/span>ect between associations<\/span> and<\/span> do not have a mechanistic understanding of <\/span>their<\/span> findings. A longitudinal analysis of<\/span> outcomes must be carried out in the future to determine any long-term <\/span>consequences<\/span> of deficient vitamin D<\/span> status during acute COVID-19 infection.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n
\u00a0<\/span><\/p>\n\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Author\u2019s Conclusions<\/span><\/h2><\/div><\/div><\/div>“<\/span><\/h2><\/div><\/div><\/div>H<\/span><\/span>igh-dose cholecalciferol booster therapy, regardless of baseline serum 25(OH)D<\/span><\/span> levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with<\/span><\/span> COVID-19. This suggests that further work should be carried out to determine what an adequate serum<\/span><\/span> level of 25(OH)D might be from large-scale population <\/span><\/span>studies, and<\/span><\/span> paves the way for future clinical<\/span><\/span> trials of cholecalciferol therapy, at multiple doses in order to assess maximum <\/span><\/span>effi<\/span><\/span>cacy<\/span><\/span>.<\/span><\/span><\/p>\n<\/div><\/div><\/div>“<\/span><\/h2><\/div><\/div><\/div><\/div><\/div>Study Design<\/span><\/h2><\/div>\n- Patients received<\/span> cholecalciferol booster therapy if they were recogni<\/span>z<\/span>ed as being either vitamin D ins<\/span>uff<\/span>i<\/span>cient (serum<\/span> 25(OH)D 25\u201350 nmol\/L) or deficient as part of routine clinical care.<\/span> In this study,<\/span> 151 (16.0%)<\/span> patients <\/span>received <\/span>high-dose <\/span>cholecalciferol<\/span> booster<\/span> therapy (<\/span>\u00b3<\/span> 280,000 IU in a time period of up to 7 weeks<\/span>).<\/span>\u00a0<\/span><\/li>\n
- Patients were divided into a primary and validation cohort. The primary cohort included 444 subjects enrolled at <\/span>Tameside<\/span> General Hospital. The validation cohort was made up of subjects enrolled at both Royal Preston Hospital and University Hospitals of Leicester. The mean ages <\/span>of the cohorts <\/span>were <\/span>\u00b3<\/span>70 years<\/span> and included 42.2-57.8 % women.<\/span>\u00a0<\/span><\/li>\n
- The primary outcome measure, COVID-19 mortality, included deaths in hospital, and deaths<\/span> following admission recorded during the data collection period, <\/span>e.g.<\/span><\/i>, following transfer or discharge.<\/span>\u00a0<\/span><\/li>\n
- Logistic regression was used to determine any relationships<\/span> between COVID-19 mortality and potential predictors, including <\/span>serum <\/span>25(OH)D levels and cholecalciferol<\/span> booster therapy<\/span>
High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study<\/span><\/span><\/span><\/h1><\/div>Take Home Message<\/span><\/h2><\/div>In this observational study, treatment with cholecalciferol booster therapy, regardless of baseline serum 25(OH)D levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with COVID-19. <\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Who<\/span><\/h2><\/div>A total of 986 <\/span>i<\/span>n-patients with a clinical diagnosis of COVID-19 recruited from three UK hospital<\/span>s<\/span>, of whom 151 (16.0%)<\/span> received cholecalciferol booster therapy.\u00a0<\/span>\u00a0<\/span><\/p>\n\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Length of Study
\n<\/span><\/p><\/h2><\/div>Patients recruited were admitted between January<\/span> 27,<\/span> 2020 and August<\/span> 5,<\/span> 2020, and data were<\/span> collected retrospectively between June<\/span> 26,<\/span> 2020 and August<\/span> 7,<\/span> 2020.<\/span>\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/b>Results<\/span><\/h2><\/div><\/div><\/div>\n- S<\/span>erum 25(OH)D levels were not associated with COVID-19 mortality in<\/span> either<\/span> the <\/span>primary <\/span>or<\/span> validation cohort, and deficient vitamin D status <\/span>(defined as <25 nmol\/L) <\/span>was not associated with COVID-19<\/span> mortality in the primary cohort.\u00a0<\/span>\u00a0<\/span><\/li>\n
- T<\/span>reatment with <\/span>high-dose <\/span>cholecalciferol <\/span>booster therapy was associated with a reduced risk of COVID-19 mortality <\/span>regardless of baseline serum 25(OH)D levels, and this <\/span>was true in both<\/span> cohorts.<\/span>\u00a0<\/span><\/li>\n<\/ul>\n<\/div><\/div><\/div><\/span><\/div><\/div><\/div><\/div><\/div>
Things to Keep in Mind<\/span><\/h2><\/div>\n- N<\/span>ot all patients had serum 25(OH)D<\/span> levels available, so <\/span>the <\/span>power <\/span>would <\/span>have been improved with more values.\u00a0<\/span>\u00a0<\/span><\/li>\n
- W<\/span>hile <\/span>the <\/span>results<\/span> are potentially generali<\/span>z<\/span>able to the UK, <\/span>similar studies<\/span> would need to be replicated in d<\/span>iff<\/span>erent <\/span>global<\/span> populations to assess <\/span>th<\/span>eir general validity.<\/span>\u00a0<\/span><\/li>\n
- D<\/span>ue to the<\/span> cross-sectional nature of this study, <\/span>the investigators <\/span>were<\/span> unable to ascertain cause and <\/span>eff<\/span>ect between associations<\/span> and<\/span> do not have a mechanistic understanding of <\/span>their<\/span> findings. A longitudinal analysis of<\/span> outcomes must be carried out in the future to determine any long-term <\/span>consequences<\/span> of deficient vitamin D<\/span> status during acute COVID-19 infection.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n
\u00a0<\/span><\/p>\n\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Author\u2019s Conclusions<\/span><\/h2><\/div><\/div><\/div>“<\/span><\/h2><\/div><\/div><\/div>H<\/span><\/span>igh-dose cholecalciferol booster therapy, regardless of baseline serum 25(OH)D<\/span><\/span> levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with<\/span><\/span> COVID-19. This suggests that further work should be carried out to determine what an adequate serum<\/span><\/span> level of 25(OH)D might be from large-scale population <\/span><\/span>studies, and<\/span><\/span> paves the way for future clinical<\/span><\/span> trials of cholecalciferol therapy, at multiple doses in order to assess maximum <\/span><\/span>effi<\/span><\/span>cacy<\/span><\/span>.<\/span><\/span><\/p>\n<\/div><\/div><\/div>“<\/span><\/h2><\/div><\/div><\/div><\/div><\/div>Study Design<\/span><\/h2><\/div>\n- Patients received<\/span> cholecalciferol booster therapy if they were recogni<\/span>z<\/span>ed as being either vitamin D ins<\/span>uff<\/span>i<\/span>cient (serum<\/span> 25(OH)D 25\u201350 nmol\/L) or deficient as part of routine clinical care.<\/span> In this study,<\/span> 151 (16.0%)<\/span> patients <\/span>received <\/span>high-dose <\/span>cholecalciferol<\/span> booster<\/span> therapy (<\/span>\u00b3<\/span> 280,000 IU in a time period of up to 7 weeks<\/span>).<\/span>\u00a0<\/span><\/li>\n
- Patients were divided into a primary and validation cohort. The primary cohort included 444 subjects enrolled at <\/span>Tameside<\/span> General Hospital. The validation cohort was made up of subjects enrolled at both Royal Preston Hospital and University Hospitals of Leicester. The mean ages <\/span>of the cohorts <\/span>were <\/span>\u00b3<\/span>70 years<\/span> and included 42.2-57.8 % women.<\/span>\u00a0<\/span><\/li>\n
- The primary outcome measure, COVID-19 mortality, included deaths in hospital, and deaths<\/span> following admission recorded during the data collection period, <\/span>e.g.<\/span><\/i>, following transfer or discharge.<\/span>\u00a0<\/span><\/li>\n
- Logistic regression was used to determine any relationships<\/span> between COVID-19 mortality and potential predictors, including <\/span>serum <\/span>25(OH)D levels and cholecalciferol<\/span> booster therapy<\/span>
Take Home Message<\/span><\/h2><\/div>In this observational study, treatment with cholecalciferol booster therapy, regardless of baseline serum 25(OH)D levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with COVID-19. <\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Who<\/span><\/h2><\/div>A total of 986 <\/span>i<\/span>n-patients with a clinical diagnosis of COVID-19 recruited from three UK hospital<\/span>s<\/span>, of whom 151 (16.0%)<\/span> received cholecalciferol booster therapy.\u00a0<\/span>\u00a0<\/span><\/p>\n\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Length of Study
\n<\/span><\/p><\/h2><\/div>Patients recruited were admitted between January<\/span> 27,<\/span> 2020 and August<\/span> 5,<\/span> 2020, and data were<\/span> collected retrospectively between June<\/span> 26,<\/span> 2020 and August<\/span> 7,<\/span> 2020.<\/span>\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/b>Results<\/span><\/h2><\/div><\/div><\/div>\n- S<\/span>erum 25(OH)D levels were not associated with COVID-19 mortality in<\/span> either<\/span> the <\/span>primary <\/span>or<\/span> validation cohort, and deficient vitamin D status <\/span>(defined as <25 nmol\/L) <\/span>was not associated with COVID-19<\/span> mortality in the primary cohort.\u00a0<\/span>\u00a0<\/span><\/li>\n
- T<\/span>reatment with <\/span>high-dose <\/span>cholecalciferol <\/span>booster therapy was associated with a reduced risk of COVID-19 mortality <\/span>regardless of baseline serum 25(OH)D levels, and this <\/span>was true in both<\/span> cohorts.<\/span>\u00a0<\/span><\/li>\n<\/ul>\n<\/div><\/div><\/div><\/span><\/div><\/div><\/div><\/div><\/div>
Things to Keep in Mind<\/span><\/h2><\/div>\n- N<\/span>ot all patients had serum 25(OH)D<\/span> levels available, so <\/span>the <\/span>power <\/span>would <\/span>have been improved with more values.\u00a0<\/span>\u00a0<\/span><\/li>\n
- W<\/span>hile <\/span>the <\/span>results<\/span> are potentially generali<\/span>z<\/span>able to the UK, <\/span>similar studies<\/span> would need to be replicated in d<\/span>iff<\/span>erent <\/span>global<\/span> populations to assess <\/span>th<\/span>eir general validity.<\/span>\u00a0<\/span><\/li>\n
- D<\/span>ue to the<\/span> cross-sectional nature of this study, <\/span>the investigators <\/span>were<\/span> unable to ascertain cause and <\/span>eff<\/span>ect between associations<\/span> and<\/span> do not have a mechanistic understanding of <\/span>their<\/span> findings. A longitudinal analysis of<\/span> outcomes must be carried out in the future to determine any long-term <\/span>consequences<\/span> of deficient vitamin D<\/span> status during acute COVID-19 infection.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n
\u00a0<\/span><\/p>\n\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Author\u2019s Conclusions<\/span><\/h2><\/div><\/div><\/div>“<\/span><\/h2><\/div><\/div><\/div>H<\/span><\/span>igh-dose cholecalciferol booster therapy, regardless of baseline serum 25(OH)D<\/span><\/span> levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with<\/span><\/span> COVID-19. This suggests that further work should be carried out to determine what an adequate serum<\/span><\/span> level of 25(OH)D might be from large-scale population <\/span><\/span>studies, and<\/span><\/span> paves the way for future clinical<\/span><\/span> trials of cholecalciferol therapy, at multiple doses in order to assess maximum <\/span><\/span>effi<\/span><\/span>cacy<\/span><\/span>.<\/span><\/span><\/p>\n<\/div><\/div><\/div>“<\/span><\/h2><\/div><\/div><\/div><\/div><\/div>Study Design<\/span><\/h2><\/div>\n- Patients received<\/span> cholecalciferol booster therapy if they were recogni<\/span>z<\/span>ed as being either vitamin D ins<\/span>uff<\/span>i<\/span>cient (serum<\/span> 25(OH)D 25\u201350 nmol\/L) or deficient as part of routine clinical care.<\/span> In this study,<\/span> 151 (16.0%)<\/span> patients <\/span>received <\/span>high-dose <\/span>cholecalciferol<\/span> booster<\/span> therapy (<\/span>\u00b3<\/span> 280,000 IU in a time period of up to 7 weeks<\/span>).<\/span>\u00a0<\/span><\/li>\n
- Patients were divided into a primary and validation cohort. The primary cohort included 444 subjects enrolled at <\/span>Tameside<\/span> General Hospital. The validation cohort was made up of subjects enrolled at both Royal Preston Hospital and University Hospitals of Leicester. The mean ages <\/span>of the cohorts <\/span>were <\/span>\u00b3<\/span>70 years<\/span> and included 42.2-57.8 % women.<\/span>\u00a0<\/span><\/li>\n
- The primary outcome measure, COVID-19 mortality, included deaths in hospital, and deaths<\/span> following admission recorded during the data collection period, <\/span>e.g.<\/span><\/i>, following transfer or discharge.<\/span>\u00a0<\/span><\/li>\n
- Logistic regression was used to determine any relationships<\/span> between COVID-19 mortality and potential predictors, including <\/span>serum <\/span>25(OH)D levels and cholecalciferol<\/span> booster therapy<\/span>
In this observational study, treatment with cholecalciferol booster therapy, regardless of baseline serum 25(OH)D levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with COVID-19. <\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div> A total of 986 <\/span>i<\/span>n-patients with a clinical diagnosis of COVID-19 recruited from three UK hospital<\/span>s<\/span>, of whom 151 (16.0%)<\/span> received cholecalciferol booster therapy.\u00a0<\/span>\u00a0<\/span><\/p>\n \u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div> Length of Study Patients recruited were admitted between January<\/span> 27,<\/span> 2020 and August<\/span> 5,<\/span> 2020, and data were<\/span> collected retrospectively between June<\/span> 26,<\/span> 2020 and August<\/span> 7,<\/span> 2020.<\/span>\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div> \u00a0<\/span><\/p>\n \u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div> H<\/span><\/span>igh-dose cholecalciferol booster therapy, regardless of baseline serum 25(OH)D<\/span><\/span> levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with<\/span><\/span> COVID-19. This suggests that further work should be carried out to determine what an adequate serum<\/span><\/span> level of 25(OH)D might be from large-scale population <\/span><\/span>studies, and<\/span><\/span> paves the way for future clinical<\/span><\/span> trials of cholecalciferol therapy, at multiple doses in order to assess maximum <\/span><\/span>effi<\/span><\/span>cacy<\/span><\/span>.<\/span><\/span><\/p>\n<\/div><\/div><\/div>Who<\/span><\/h2><\/div>
\n<\/span><\/p><\/h2><\/div><\/b>Results<\/span><\/h2><\/div><\/div><\/div>
\n
<\/span><\/div><\/div><\/div><\/div><\/div>Things to Keep in Mind<\/span><\/h2><\/div>
\n
Author\u2019s Conclusions<\/span><\/h2><\/div><\/div><\/div>
“<\/span><\/h2><\/div><\/div><\/div>
“<\/span><\/h2><\/div><\/div><\/div><\/div><\/div>
Study Design<\/span><\/h2><\/div>
\n